Skip to main content

Advertisement

Springer Nature Link
Log in

Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Objective The therapeutic benefit of inhaled corticoids in bronchiectasis not due to cystic fibrosis is still not well documented. The aim of the present study was to assess the efficacy and safety of inhaled corticoids in this disease. Setting This study was conducted at a tertiary university hospital in the city of Barcelona, Catalonia, (Spain). Method A prospective, double-blind, parallel, placebo-masked study was conducted. Seventy-seven patients (40 women; mean age: 68 years) were randomly assigned to receive either 400 mcg budesonide twice daily or placebo and were regularly reviewed for six months. Results Differences in forced vital capacity and forced expiratory volume in the first second between the beginning and end of the study were not significantly lower in the budesonide group than in the placebo group, either in absolute values [−17.4 (386.9) versus −21.4 (375.5)] or in percentages [−1.9(9.5) versus −2.8 (11.6)]. Microbiological criteria applied to evaluate changes between the beginning and end of the study showed no worsening in the budesonide group compared with the control group, whereas a non-significant improvement was obtained in 8.1 % of cases in the budesonide group compared to 3 % in the placebo group. Although significance was only achieved for sputum eosinophils (p = 0.021), a consistent tendency towards improvement was also observed in secondary end-points (symptoms, number and duration of exacerbations, quality of life, sputum cytology and interleukin-8) in the budesonide group. Conclusion Although further studies are required, inhaled corticoid treatment may be efficacious and safe in bronchiectasis not due to cystic fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
€34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Levine SJ. Bronchial epithelial cell cytokine interactions in airway inflammation. J Investig Med. 1995;43:241–9.

    PubMed  CAS  Google Scholar 

  2. Wilson R. The pathogenesis and management of bronchial infections: the vicious cycle of respiratory decline. Rev Contemp Pharmacother. 1992;3:103–12.

    Google Scholar 

  3. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–50.

    Article  PubMed  CAS  Google Scholar 

  4. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2010. Available from: http://www.ginasthma.org.

  5. From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive lung disease (GOLD) 2010. Available from: http://www.goldcopd.org.

  6. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs. 2007;67:965–74.

    Article  PubMed  CAS  Google Scholar 

  7. Inhaled corticosteroids for cystic fibrosis (Review). The Cochrane collaboration 2009.

  8. Inhaled corticosteroids for bronchiectasis (Review). The Cochrane collaboration 2009.

  9. Giner J, Basualdo LV, Casan P, Hernandez C, Macián V, Martínez I, et al. Normativa sobre la utilización de fármacos inhalados. Recomendaciones SEPAR. Arch Bronconeumol. 2000;36:34–43.

    PubMed  CAS  Google Scholar 

  10. Casals T, Nunes V, Palacio A, Giménez J, Gaona A, Ibáñez N, et al. Cystic fibrosis in Spain: high frequency of mutation G542X in the Mediterranean coastal area. Hum Genet. 1993;91:66–70.

    Article  PubMed  CAS  Google Scholar 

  11. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30:1326–36.

    Article  Google Scholar 

  12. Ferrer M, Alonso J, Prieto L, Plaza V, Monso E, Marrades R, et al. Validity and reliability of the St George’s Respiratory Questionnaire alter adaptation to a different language and culture: the Spanish example. Eur Respir J. 1996;9:1160–6.

    Article  PubMed  CAS  Google Scholar 

  13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.

    Article  PubMed  CAS  Google Scholar 

  14. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9(6):1174–80.

    Article  PubMed  CAS  Google Scholar 

  15. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clinic Proc. 1975;50:339–44.

    CAS  Google Scholar 

  16. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–6.

    PubMed  CAS  Google Scholar 

  17. Kapur N, Bell S. Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009; 1. Art. no.: CD000996. doi:10.1002/14651858.CD000996.pub2.

  18. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31:396–406.

    Article  PubMed  CAS  Google Scholar 

  19. Phua GC, Macintyre NR. Inhaled corticosteroids in obstructive airway disease. Respir Care. 2007;52:852–8.

    PubMed  Google Scholar 

  20. Sutherland R, Allmers H, Ayas NT, Venn J, Martin RJ. Inhaled corticosteroids reduce progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937–41.

    Article  PubMed  CAS  Google Scholar 

  21. Escotte S, Tabary O, Dusser D, Majer-Teboul C, Puchelle E, Jacquot J. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway. Eur Respir J. 2003;21:574–81.

    Article  PubMed  CAS  Google Scholar 

  22. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varguese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86:121–4.

    Article  PubMed  CAS  Google Scholar 

  23. Tsang KWT, Ho PL, Lam WK, Ip MSM, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158:723–7.

    PubMed  CAS  Google Scholar 

  24. Joshi JM, Sundaram P. Role of inhaled steroids in stable bronchiectasis. Indian Pract. 2004;57(4):243–5.

    Google Scholar 

  25. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60:239–43.

    Article  PubMed  CAS  Google Scholar 

  26. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ, Carratalá A, Pastor M. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100:1623–32.

    Article  PubMed  Google Scholar 

  27. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828–38.

    Article  PubMed  CAS  Google Scholar 

  28. Angrill J, Agustí C, de Celis R, Rañó A, Gozalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Christine O’Hara for her help with the English translation of the manuscript and Rosa Llòria for editorial assistance.

Funding

This work was supported by the Catalan Foundation of Pneumology (FUCAP) through a grant attributed to RH, MED and RO.

Conflicts of interest

None declared.

Author information

Authors and Affiliations

  1. Servei de Pneumologia, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron, 119-129, 08035, Barcelona, Catalonia, Spain

    Rosana Hernando, María Estrella Drobnic, María Jesús Cruz & Ramon Orriols

  2. Parc Sanitari St. Joan de Déu, Sant Boi de Llobregat, Barcelona, Catalonia, Spain

    Rosana Hernando

  3. CIBER Enfermedades Respiratorias (CIBERES), Barcelona, Catalonia, Spain

    María Estrella Drobnic, María Jesús Cruz & Ramon Orriols

  4. Servei de Microbiologia, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

    Adelaida Ferrer

  5. Servei de Farmàcia, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

    Pilar Suñé & J. Bruno Montoro

Authors
  1. Rosana Hernando
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. María Estrella Drobnic
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. María Jesús Cruz
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Adelaida Ferrer
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Pilar Suñé
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. J. Bruno Montoro
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Ramon Orriols
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to J. Bruno Montoro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernando, R., Drobnic, M.E., Cruz, M.J. et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm 34, 644–650 (2012). https://doi.org/10.1007/s11096-012-9659-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-012-9659-6

Keywords